The goal of this research proposal is to determine the mechanism(s) by which mutant isocitrate dehydrogenase 1 (IDH1) causes brain tumors to be less aggressive. The most common type of brain tumor is the diffusely infiltrative glioma;these tumors cannot be completely excised surgically, and are difficult to treat with radiation and chemotherapy. Thus, infiltrative gliomas are incurable. A specific point mutation in IDH1 (and a less common analogous mutation in IDH2) has been found to be quite frequent in these gliomas. When present, it is a powerful favorable prognostic factor, being strongly associated with longer patient survival. Mutant IDH1 has recently been shown to produce a novel compound, 2-hydroxyglutarate (2-HG). However, the effects of mutant IDH1 and 2-HG on glioma cells are unknown. Other work showed that 2-HG causes oxidative stress in nonneoplastic tissue models, and our preliminary data indicate that 2-HG is toxic to glioma cells and induces autophagy, ERK activation, and reactive oxygen species production. We therefore hypothesize that the improved survival imparted by mutant IDH1 in diffuse gliomas is due to 2-HG-induced production of reactive oxygen species, leading to oxidative damage and cell death. We also hypothesize that the cell death is primarily by autophagy, a form of programmed cell death involving lysosomes that has been shown to be prominent in many gliomas. To test these hypotheses, glioma cells will be treated with 2-HG or transfected with mutant IDH1, and multiple well-described markers of autophagy and reactive oxygen species will be measured. Response of glioma cells to autophagy and reactive oxygen species modulation will be assessed. For patient-derived tumor biopsies and human-mouse xenografts, immunohistochemical markers of autophagy and oxidative stress will be quantified and correlated with IDH mutation status. Success in this project would determine whether mutant IDH1 causes increased oxidative stress and autophagy in gliomas, thereby producing a less aggressive glioma compared to tumors that are wild type for IDH1. This knowledge could then be exploited to develop novel ways of treating gliomas. I am fortunate to have been mentored by exceptional scientists and physicians, thus instilling in me a desire to pursue a career that synthesizes what I have learned as a scientist and neuropathologist.My graduate and postdoctoral work in neuroscience and my work in neuro-oncology have given me a diverse array of techniques and approaches that will be used in this project. My current position as an Assistant Professor in the Department of Pathology in the University of Kentucky offers the ideal opportunity to pursue my goal of being an independent investigator. I have nine person-months (75%) of guaranteed protected time for research, separate laboratory space that has been fully equipped, a full-time technician to increase output, and sufficient funds to conduct experiments for the next four years. All this has been put in place by my chairman, Dr. Paul Bachner, independent of my success in securing extramural funding. I also benefit from a collaborative environment, superb mentorship by Drs. Natasha Kyprianou, Arie Perry, and Jeremy Rich, and excellent technical resources. Now that I have completed my clinical training, the funding provided by this K08 award would allow me to develop as an independent investigator. Furthermore, the project described in this proposal provides a superb opportunity to discover why mutant IDH1 imparts a more favorable survival in patients afflicted with gliomas, in turn helping to identify pathways and targets for effective therapeutic interventions.
This research explores why mutant isocitrate dehydrogenase 1, an abnormal enzyme found in many brain tumors, is such a powerful marker of longer patient survival. Discovering why this is so will help find new ways to treat these incurable tumors. The written critiques and criteria scores of individual reviewers are provided in essentially unedited form in the Critique section below. Please note that these critiques and criteria scores were prepared prior to the meeting and may not have been revised subsequent to any discussions at the review meeting. The Resume and Summary of Discussion section above summarizes the final opinions of the committee.
|Huang, Tianzhi; Alvarez, Angel A; Pangeni, Rajendra P et al. (2016) A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. Nat Commun 7:12885|
|Nikiforova, Marina N; Wald, Abigail I; Melan, Melissa A et al. (2016) Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol 18:379-87|
|Unruh, Dusten; Schwarze, Steven R; Khoury, Laith et al. (2016) Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol 132:917-930|
|Geng, Feng; Cheng, Xiang; Wu, Xiaoning et al. (2016) Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis. Clin Cancer Res 22:5337-5348|
|Horbinski, Craig (2015) Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 17:478-9|
|Xie, Qi; Wu, Qiulian; Mack, Stephen C et al. (2015) CDC20 maintains tumor initiating cells. Oncotarget 6:13241-54|
|Schonberg, David L; Miller, Tyler E; Wu, Qiulian et al. (2015) Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell 28:441-55|
|Lee, Tae Jin; Haque, Farzin; Shu, Dan et al. (2015) RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget 6:14766-76|
|Zhou, Pengcheng; Erfani, Sonia; Liu, Zeyi et al. (2015) CD151-Î±3Î²1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion. Oncotarget 6:29675-93|
|Xie, Qi; Wu, Qiulian; Horbinski, Craig M et al. (2015) Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci 18:501-10|
Showing the most recent 10 out of 35 publications